Submissions from 2025
Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma, Toni K. Choueiri, Moshe C. Ornstein, Pedro C. Barata, Marc R. Matrana, Jaime R. Merchan, Craig Gedye, Clara Hwang, Rohit Kumar, Jae Lyun Lee, Yinghui Guan, Mohammad Ghasemi, Syed Quadri, Christopher Negro, Jianfen Chen, Paul G. Foster, Manish Monga, Bradley A. McGregor, Sun Young Rha, and Alexandra Drakaki
Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma, Toni K. Choueiri, Moshe C. Ornstein, Pedro C. Barata, Marc R. Matrana, Jaime R. Merchan, Craig Gedye, Clara Hwang, Rohit Kumar, Jae Lyun Lee, Yinghui Guan, Mohammad Ghasemi, Syed Quadri, Christopher Negro, Jianfen Chen, Paul G. Foster, Manish Monga, Bradley A. McGregor, Sun Young Rha, and Alexandra Drakaki
Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141), Toni Choueri, Moshe Ornstein, Pedro C. Barata, Marc Matrana, Jaime Merchan, Craig Gedye, Clara Hwang, Rohit Kumar, Jae Lyun Lee, Yinghui Guan, Mohammad Ghasemi, Syed Quadri, Chris Negro, Jianfen Chen, Paul Foster, Deepti Warad, Bradley A. McGregor, Sun Young Rha, and Alexandra Drakaki
Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141), Toni Choueri, Moshe Ornstein, Pedro C. Barata, Marc Matrana, Jaime Merchan, Craig Gedye, Clara Hwang, Rohit Kumar, Jae Lyun Lee, Yinghui Guan, Mohammad Ghasemi, Syed Quadri, Chris Negro, Jianfen Chen, Paul Foster, Deepti Warad, Bradley A. McGregor, Sun Young Rha, and Alexandra Drakaki
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATENORTH AMERICA): NRG-GI008, Arvind Dasari, Guan Yu, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Ibrahim Halil Halil Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Christopher H. Lieu
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008, Arvind Dasari, Guan Yu, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Ibrahim H. Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Christopher Hanyoung Lieu
Fusing quality improvement and education frameworks to reduce delays in tumor genotyping at community cancer centers, Carmine Deluca, Jeremy Stapp, Chris Kriz, Jessica Massey, Thomas Loss, Zyad Kafri, Michael Beyer, John Marshall, Yuan Ying, Jonathan Treisman, and Zeeshan Ali
Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S- 531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors, Toshihiko Doi, Taroh Satoh, Noboru Yamamoto, Clara Hwang, Omid Hamid, Anthony J. Olszanski, Feng Zeng, Takayuki Katsube, Michael J. Chisamore, and Tomohiko Harada
Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+NSCLC, Alexander E. Drilon, Byoung Chul Cho, Jessica J. Lin, Benjamin J. Solomon, Chia-Chi Lin, Adrianus Johannes de Langen, Enriqueta Felip, Joel W. Neal, Stephen V. Liu, Ross A. Soo, Steven Kao, Jürgen Wolf, Geoffrey Liu, Christina S. Baik, Christophe Dooms, Misako Nagasaka, A. J. van der Wekken, D. Ross Camidge, Tatsuya Yoshida, Chien-Chung Lin, Gee-Chen Chang, Myung-Ju Ahn, Jessica R. Bauman, Shirish M. Gadgeel, Antonio Calles, Elvire Pons-Tostivint, Daniel Shao Weng Tan, Melissa Johnson, Chiara Bennati, and Gianluca Spitaleri
A systematic review of the impact of artificial intelligence in pancreatic cancer detection, Jahnavi Ethakota, Bipneet Singh, Sakshi Bai, Danesh Kumar, and Devin B. Malik
Baseline participant characteristics from PATHFINDER 2, a prospective interventional study of a multi-cancer early detection test in a population setting, Shirish M. Gadgeel, Nima Nabavizadeh, Dax Kurbegov, Charles McDonnell III, James W. Lillard Jr., Marc Matrana, Alan Roth, Andrea Johnston, Sami Tahhan, Rami Owera, Matthew Margolis, Anuraag Kansal, Margarita Lopatin, Margaret McCusker, and Karthik V. Giridhar
Baseline participant characteristics from PATHFINDER 2, a prospective interventional study of a multi-cancer early detection test in a population setting, Shirish M. Gadgeel, Nima Nabavizadeh, Dax Kurbegov, Charles McDonnell III, James W. Lillard Jr., Marc Matrana, Alan Roth, Andrea Johnston, Sami Tahhan, Rami Owera, Matthew Margolis, Anuraag Kansal, Margarita Lopatin, Margaret McCusker, and Karthik V. Giridhar
Real-World Study in Patients With ALK plus Metastatic Non-Small Cell Lung Cancer (mNSCLC) Treated With First-Line (1L) Lorlatinib, Shirish M. Gadgeel, L. Stansfield, P. Ramachandran, O. Emidio, A. Kotomale, N. Rifi, L. Alejandro, and D. Abrahami
Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation, Valentina Gambardella, Alejandro Navarro, Prantesh Jain, José M. López-Picazo, Gonzalo Fernandez Hinojal, Jon Zugazagoitia, Maria J. de Miguel, Shirish M. Gadgeel, Sajjad A. Bhatti, Pedro Rocha, Anna Vilalta-Lacarra, Esteban R. Imedio, Sandrine Micallef, Jonathan Wessen, Vito Dozio, Rikke F. Franzen, Anne Bellon, and Luis G. Paz-Ares
Treatment and outcomes of breast cancer with leptomeningeal disease: Real-world experience in the African American population, Bipin Ghimire, Maria Jamil, and Marian Girgis
Efficacy of systemic therapy in breast cancer with CNS metastases: “Real-world” experience, Bipin Ghimire, Maria Jamil, Lisa R. Rogers, and Marian Girgis
Efficacy of systemic therapy in breast cancer with CNS metastases: “Real-world” experience, Bipin Ghimire, Maria Jamil, Lisa R. Rogers, and Marian Girgis
MM-259: Impact of the International Myeloma Working Group (IMWG) SLiM Criteria on Multiple Myeloma Management: A Tertiary Care Center Experience, Dhairya Gor, Tasnim Rehman, Anju Pradeep, Sunita Ghosh, and Philip Kuriakose
Safety and Efficacy of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) for the Treatment of Sickle Cell Disease with Severe Vaso-Occlusive Crises: Results from the Ongoing Phase 1/2 Beacon Study, Ashish O. Gupta, Akshay Sharma, Haydar Frangoul, Jignesh Dalal, Julie Kanter, Asif Alavi, John F. DiPersio, Mary Eapen, Jennifer J. Jaroscak, Ernesto Ayala, Edward D. Ziga, Stacey Rifkin-Zenenberg, Alex C. Minella, Guo Chen, Yinzhong Chen, Priya S. Chockalingam, Ling Lin, Marcelyne Joseney-Antoine, Leanne Ianniello, Beth Gardner, Adam J. Hartigan, Giuseppe Ciaramella, Sunita Goyal, Amy Simon, Alexis A. Thompson, and Matthew M. Heeney
BASE EDITING FOR SICKLE CELL DISEASE: ONGOING RESULTS FROM THE BEACON STUDY EVALUATING THE SAFETY AND EFFICACY OF BEAM-101, THE FIRST BASE-EDITED AUTOLOGOUS CD34+ HSPC ONE-TIME CELL THERAPY, Ashish Gupta, Akshay Sharma, Jignesh Dalal, Julie Kanter, Ernesto Ayala, John DiPersio, Haydar Frangoul, Markus Mapara, Jennifer Jaroscak, Asif Alavi, Mary Eapen, Stacey Rifkin-Zenenberg, Edward Ziga, Elizabeth Stenger, Rabi Hanna, Tami D. John, Shanna White, Thomas S. Bowman, Yinzhong Chen, Sarah Chesler, Priya S. Chockalingam, Ling Lin, John J. Ko, Marcelyne Joseney-Antoine, Leanne Ianniello, Guo Chen, Beth Gardner, Sunita Goyal, Amy Simon, and Alexis Thompson
Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study, Ashish Gupta, Akshay Sharma, Haydar Frangoul, Julie Kanter, Markus Mapara, Jignesh Dalal, Asif Alavi, Jennifer Jaroscak, Ernesto Ayala, John DiPersio, Edward D. Ziga, Mary Eapen, Stacey Rifkin-Zenenberg, Srikanth Ambati, Yinzhong Chen, Sarah Chesler, Marcelyne Joseney-Antoine, Leanne Ianniello, Bahru Habtemariam, Priya Chockalingam, Ling Lin, Sunita Goyal, Amy Simon, Alexis Thompson, and Matthew Heeney
298MO Clinical activity of emiltatug ledadotin (Emi-Le), a B7-H4-directed ADC, in patients with TNBC who received at least one prior topoisomerase-1 inhibitor (Topo-1) ADC, E. P. Hamilton, H. Han, N. Abuhadra, K. Kalinsky, N. P. McAndrew, A. Spira, N. Chan, K. Kelley, R. Parajuli, J. O'Shaughnessy, D. Starks, G. Wulf, Amy M. Weise, A. Chaudhry, J. S. Wang, D. L. Richardson, F. Meric-Bernstam, R. Burger, C. Bradshaw, and A. Giordano
Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4- directed dolasynthen antibody-drug conjugate, Erika P. Hamilton, Hyo S. Han, Kevin Kalinsky, Nour Abuhadra, Nicholas P. McAndrew, Alexander I. Spira, Nancy Chan, David Starks, Gerburg M. Wulf, Arvind Chaudhry, Kristen Kelley, Ritesh Parajuli, Judy S. Wang, Joyce O'Shaughnessy, Amy M. Weise, Debra L. Richardson, Dario R. Roque, Renata Ferrarotto, Nora Zizlsperger, and Antonio Giordano
Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC, Hyo S. Han, Kevin Kalinsky, Nour Abuhadra, Antonio Giordano, David Starks, Gerburg M. Wulf, Nicholas P. McAndrew, Joyce O'Shaughnessy, Alexander I. Spira, Nancy Chan, Kristen Kelley, Ritesh Parajuli, Amy M. Weise, Arvind Chaudhry, Judy S. Wang, Debra L. Richardson, Dario R. Roque, Funda Meric-Bernstam, Caroline Rogalski, and Erika P. Hamilton
Transcriptomic Profiling Identifies a Prognostic and Predictive Immune Signature in Patients (Pts) With Lung Squamous Cell Carcinoma (LUSC), M. K. Hashki, N. N. Al-Bzour, A. N. Al-Bzour, J. Al Rawabdeh, O. M. Younis, and Fawzi Abu Rous
CHARACTERISTICS, TREATMENT PATTERNS, AND OUTCOMES OF AFRICAN AMERICAN VERSUS CAUCASIAN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POST HOC ANALYSIS OF TRUMPET REGISTRY, Clara Hwang, James Symanowski, Neal Shore, David Russell, Pavol Kral, Dina Elsouda, Nader El-Chaar, and Lawrence Karsh
Investigating the roles of GLI transcription factors in the pancreatic cancer microenvironment, Paola Isabel, Medina Cabrera, Michael Scales, Nina G. Steele, Nicole Franks, Hannah Dear, Giulia Biffi, David Tuveson, Marina Pasca di Magliano, and Benjamin Allen
Phase 3 eVOLVE-Lung02 Trial of Volrustomig plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic NSCLC With PD-L1 TC <50%, M. L. Johnson, E. Arriola, T. Kato, N. Girard, Shirish M. Gadgeel, M. Majem Tarruella, T. Newsom-Davis, M. Polaczek, X. Chen, K. Stefaniak, C. Lowery, N. Angra, G. Doherty, and M-J. Ahn
Questioning Protocols: The Case Against Routine Post-Lumpectomy Mammography for Patients with Calcifications, Christine Joliat, Jessica Bensenhaver, Ena Muhamedovic, Marcus Brown, Shermeen Rahmat, Anne Patterson, Laura Dalla Vecchia, Lindsay Petersen, Anna Lehrberg, S. David Nathanson, and Theresa Schwartz
Breaking Barriers: Enhancing Access to Genetic Testing for All Breast Cancer (BC) Patients, Christine M. Joliat, Jessica Bensenhaver, Ena Muhamedovic, Theresa Schwartz, Laura Dalla Vecchia, Laura Susick, Lindsay Petersen, and Anna Lehrberg
Vascular heterogeneity influences treatment response in pancreatic cancer, Samantha B. Kemp, William B. Sullivan, Benjamin M. Kahn, Jonathan H. Sussman, Il-Kyu Kim, Takeshi Katsuda, Sidney Mahan, Margo I. Orlen, Samuel D. Zwernik, Kailee M. G, Steele Agnieszka K, Witkiewicz Erik S, Knudsen Ben Z, and Stanger #REF! #REF!
Vascular heterogeneity influences treatment response in pancreatic cancer, Samantha B. Kemp, William B. Sullivan, Benjamin M. Kahn, Jonathan H. Sussman, Il-Kyu Kim, Takeshi Katsuda, Sidney Mahan, Margo I. Orlen, Samuel D. Zwernik, Kailee M. Hartway, Nina G. Steele, Agnieszka K. Witkiewicz, Erik S. Knudsen, and Ben Z. Stanger
NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered non-small cell lung cancer: The phase 1 HEROEX-1 study, Xiuning Le, Zofia Piotrowska, Alexander I. Spira, Christina S. Baik, Maria Q. Baggstrom, Gerald S. Falchook, Joel W. Neal, Shirish M. Gadgeel, Gilberto Lopes, Melissa L. Johnson, Jonathan W. Riess, Danny Nguyen, Lisa Morelli, Danieska Sandino, Steven Margossian, Vivek Upadhyay, and Fernando Santini
Updated Clinical Results From FURTHER: A Study of Firmonertinib in TKI-Naive, Advanced NSCLC With EGFR PACC Mutations, X. Le, Y. Yu, Y. Zhao, D. Planchard, Y. Cheng, X. Li, Shirish M. Gadgeel, J. Zhang, A. Spira, H. Hayashi, J. Riess, S. Kitazono, N. Leighl, B. Gao, O. Juan-Vidal, A. J. de Langen, J. Mazieres, M. Perol, Y. Jiang, T. Hu, J. Huang, N. Baio, L. Musib, M. Kowanetz, S. Wang, W. Leung, S. Yea, J. Hsu, and J. Wang
Proteogenomic characterization of antibody-drug conjugate target expression profiles in transcriptional subtypes of small cell lung cancer, Edwin Lin, Mitch Singstock, Sanad Alhushki, Sameer S. Deshmukh, Changde Cheng, Kayla Goliwas, Jessy Deshane, Abdul R. Naqash, Fawzi Abu Rous, Rajat Thawani, and Aakash Desai
Palazestrant (OP-1250) plus ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced breast cancer (ABC), N. Lin, J. Chien, C. X. Ma, J. A. Mouabbi, V. Abramson, D. A. Potter, J. Sparano, H. T. Khong, J. Chaves, A. Tan, C. A. Alemany, D. Sabanathan, Randa Loutfi, L. Sun, M. Shaw, D. Vecchio, and V. Borges
Efficacy and Safety of Pralsetinib in Patients With Advanced Ret Fusion-Positive NSCLC: Phase 1/2 ARROW Study Final Data, G. Lopes, J. Gainor, V. Subbiah, D. Bowles, R. Doebele, A. Mansfield, C. Baik, Shirish M. Gadgeel, G. Kalemkerian, S-H. I. Ou, C. Becerra, M. Evangelist, S. Liu, J. Melear, A. Saxena, A. Thomassen, S. Wang, and B. Besse
Efficacy and safety of pralsetinib in patients with advanced RET-fusion-positive NSCLC: Final data from the phase 1/2 ARROW study, Gilberto Lopes, Justin F. Gainor, Vivek Subbiah, Daniel W. Bowles, Robert C. Doebele, Aaron S. Mansfield, Christina S. Baik, Shirish M. Gadgeel, Gregory P. Kalemkerian, Sai-Hong I. Ou, Carlos R. Becerra, Makenzi C. Evangelist, Stephen V. Liu, Jason M. Melear, Ashish Saxena, Amber Thomassen, Sophia Wang, and Benjamin Besse
SECONDARY HYPERTENSION AND ACUTE KIDNEY INJURY IN IGA NEPHROPATHY: A CASE REPORT, Joeita F. Macfield, William Mann, Mustafa Saadi, and Maria Jamil
The differential effect of stromal genes on gemcitabine/nab-paclitaxel (GN) and GN/cisplatin (GCN) outcomes in advanced pancreatic adenocarcinoma (aPDAC), Himil Mahadevia, Sharon Wu, Robert R. McWilliams, Umair Majeed, Jason S. Starr, Jeremy C. Jones, Osama M. MoSalem, Conor O'Donnell, Daniel H. Ahn, Joanne Xiu, Hani El Shawa, George W. Sledge Jr., Philip A. Philip, Ninad Kulkarni, Sanjay Goel, David Spetzler, Harshabad Singh, Mitesh J. Borad, Tanios S. Bekaii-Saab, and Hani M. Babiker
OUTCOMES of CAR T-CELL THERAPY (CART19) for B-ALL: A GOCART COALITION REPORT on BEHALF of the PDWP, ALWP, and CTIWP of the EBMT, Valentín O. Maldonado, Jacques-Emmanuel Galimard, Giorgio Ottaviano, Anna Alonso-Saladrigues, Shatha Farhan, Sowjana Vuyyala, Eva Michel, Fizza Imran, Nazaret Sánchez Sierra, Nuria Martinez-Cibrián, Samppa Ryhänen, Richard Mitchell, Stephan Mielke, Soeren L. Petersen, Anne Sirvent, Thomas Pabst, Jürgen Kuball, Pere Barba, Antonio Pérez-Martínez, Andishe Attarbaschi, Arnon Nagler, Jose A. Pérez-Simón, Malte von Bonin, Emma Nicholson, David Beuvais, Federica Sora, Muriel Paganessi, Olaf Penack, Cristina Castilla Llorente, and Yves Beguin
Assessing and enhancing nurse-physician communication in the infusion center to improve patient care, Kyle McElyea, Abdel-Azez Abu-Samak, Kimberly Boldig, Linda Albusoul, Kunj Patel, Kashmira Wani, Harita Soni, and Vijaya Donthireddy
Fianlimab plus cemiplimab in patients with advanced melanoma: Subgroup analyses by blinded independent central review, Meredith McKean, Amy Weise, Kyriakos P. Papadopoulos, John Crown, Sajeve S. Thomas, Janice Mehnert, John Kaczmar, Kevin B. Kim, Nehal J. Lakhani, Melinda Yushak, Jayakumar Mani, Fang Fang, Shuquan Chen, Jingxiao Chen, Laura Brennan, JuAn Wang, Israel Lowy, Mark Salvati, Matthew G. Fury, K. Lewis, and O. Hamid
Comprehensive Patient Reported Outcomes (PROs) from NRG LU005: A Randomized Trial Of Chemoradiation (CRT) ± Atezolizumab In Limited-Stage Small Cell Lung Cancer (LS-SCLC), Benjamin Movsas, C. Hu, K. A. Higgins, H. J. Ross, S. K. Jabbour, D. E. Kozono, T. K. Owonikoko, C. Xiao, T. Shoji, B. Faller, P. Mohindra, E. G. Dib, J. M. Brownstein, S. G. Chun, C. Kuzma, R. Kotecha, A. A. Onitilo, R. Paulus, J. D. Bradley, and D. W. Bruner
Two Decades of Extracorporeal Photopheresis for the Treatment of Steroid-Refractory Acute Graft-Versus-Host-Disease: A Meta-Analysis, Zaid M. Muhanna, Ahmad Issa, Jehad Yasin, Leen Alkuttob, Maya El-Niss, Muaath Alsufi, and Shatha Farhan
7MO: A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC), E. Nadal, A. Rittmeyer, F. De Marinis, D. H. Lee, Shirish M. Gadgeel, N. Vilariño, E. Bria, S. Arulananda, E. H. Cronenberg, V. Antic, E. Bennett, Y. Hu, K. Madden-Raja, P. Williams, H. Prizant, and S. Popat
A phase II trial of tobemstomig (tobe) plus platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) plus chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC), E. Nadal, A. Rittmeyer, F. De Marinis, D. H. Lee, Shirish M. Gadgeel, N. Vilariño, E. Bria, S. Arulananda, E. H. Cronenberg, V. Antic, E. Bennett, Y. Hu, K. Madden-Raja, P. Williams, H. Prizant, and S. Popat
Budesonide for Engraftment Fever Prophylaxis: A Single Center Randomized Study Interim Analysis, Klodiana Neme, Swathi Srikantan, Izabela Mazur, Nancy Mikulandric, Josephine Emole, Asif Alavi, Edward Peres, Muneer H. Abidi, and Shatha Farhan
Benchmarking clinical reasoning and accuracy of large language models on breast oncology multiple-choice questions, Roupen Odabashian, Ameer S. Basta, Ritu Sidgal, Austin Chao, Trevor Lin, Wid Alhassani, Michael T. Aboujaoude, L. Henry Bryant III, Gregory Dyson, Suha Soni, Padmapriya Muthu, Ali Haider, Hiba Jabbour Aida, Lubina Arjyal, Lawrence E. Flaherty, and Jailan Elayoubi
Benchmarking clinical reasoning and accuracy of large language models on breast oncology multiple-choice questions, Roupen Odabashian, Ameer S. Basta, Ritu Sidgal, Austin Chao, Trevor Lin, Wid Alhassani, Michael T. Aboujaoude, L. Henry Bryant III III, Gregory Dyson, Suha Soni, Padmapriya Muthu, Ali Haider, Hiba Jabbour Aida, Lubina Arjyal, Lawrence E. Flaherty, and Jailan Elayoubi
A nation's uneven battle: Trends and regional disparities in cancer mortality, Taiwo Opaleye-Enakhimion, Muhammad Ismail, Mian Z. Jan Kakakhel, Pranjal Singh, Ahmed Abdullah, Husnain Ahmad, Muneeb U. Rehman, and Hamna Jawad
Delayed or upfront brain radiotherapy in treatment-naïve lung cancer patients with asymptomatic or minimally symptomatic brain metastases and ALK rearrangements (DURABLE), Joshua D. Palmer, Nathaniel J. Myall, Erin L. Schenk, Fawzi Abu Rous, Lai Wei, Carly Pilcher, Brian Spahnie, Charles D. Tobin, Kimberly Cameron, and Dwight H. Owen
Delayed or upfront brain radiotherapy in treatment-naïve lung cancer patients with asymptomatic or minimally symptomatic brain metastases and ALK rearrangements (DURABLE), Joshua D. Palmer, Nathaniel J. Myall, Erin L. Schenk, Fawzi Abu Rous, Lai Wei, Carly Pilcher, Brian Spahnie, Charles D. Tobin, Kimberly Cameron, and Dwight H. Owen
PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC), Vincent J. Picozzi, Hani M. Babiker, Sreenivasa R. Chandana, Bohuslav Melichar, Anup Kasi, Gang Jin, Javier Gallego, Andrea J. Bullock, Hao Chunyi, Lucjan Wyrwicz, Arsen Osipov, Christelle De La Fouchardiere, Tomislav Dragovich, Woo Jin Lee, Kynan Feeney, Philip Philip, Makoto Ueno, Eric Van Cutsem, Thomas Seufferlein, and Teresa Macarulla
A PHASE 1/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF TNG260 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH STK11-MUTATED ADVANCED SOLID TUMORS, Salman R. Punekar, Gerald S. Falchook, Alexander I. Spira, David J. Kwiatkowski, Ferdinandos Skoulidis, David R. Spigel, Jonathan W. Goldman, Judy S. Wang, Shirish M. Gadgeel, Gilad Gordon, Leanne G. Ahronian, Alice W. Tsai, Suleman S. Hussain, Iga Angelone, Maxim Pimkin, Maeve Waldron-Lynch, Adam S. Crystal, and Mark M. Awad
TREATMENT WITH DIACYLGLYCEROL KINASE (DGK) ALPHA SPECIFIC INHIBITOR BAY2862789 EXHIBITS COMBINATION POTENTIAL WITH DGK ZETA INHIBITION IN BIOMARKER ASSAYS DURING FIH MONOTHERAPY TRIAL, Helge G. Roider, Lidia Sacchetto, Dennis Kirchhoff, Nicole Schubert, Stefanie Reif, Bart Ploeger, Konstantin Lang, Anke Weispfenning, Janine Noth, Teresa Lunt, Jasminka Cormarkovic-dragovic, Laura Hunt, Jamina Eckhard-Dietrich, Andrea Frohwann, Sook Hee Hong, Guru P. Sonpavde, Kyriakos P. Papadopoulos, Enriqueta Felip, Aaron Hansen, Javier Garcia-Corbacho, Jeong Eun Kim, Ofra Maimon, Shirish M. Gadgeel, Tae Min Kim, Ravit Geva, Christoph Mancao, Leila Khoja, and David Schaer
Kpg-818, a novel cereblon (CRBN) modulator, in patients with hematological malignancies: Results of a Phase 1, open-label, multiple ascending dose study, Aaron Rosenberg, Cristiana Costa, Nirav Shah, Ahmad Mattour, Eudardo Miranda, Jing-Zhou Hou, Chuansheng Ge, Qiaoyun Yu, Juanjuan Wang, Huaping Wei, Lizhi Zhao, and Yao Wang
Distinct Predictive Effects of PD-L1 Tps on Immunotherapy Outcomes and Immunophenotype in Squamous Versus Non-Squamous NSCLC, V. Santo, A. Elkrief, K. Concannon, A. Di Federico, M. M. Gandhi, F. Pecci, E. Garbo, A. Dodi, E. Gariazzo, F. Paoloni, M. Aldea, L. Landi, L. M. Sholl, S. J. Rodig, Fawzi Abu Rous, M. Tiseo, F. Cappuzzo, A. J. Schoenfeld, N. Vokes, and B. Ricciuti
Real-world outcomes of enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma at an urban academic center, Muhammad A. Shahid, Kiana Sadri, Keshav Sharma, Margaret Warren, Sunita Ghosh, and Clara Hwang
Inflammatory bowel disease and risk of cancer: A nationwide study, Abhishek Singh, Alamjeet K. Sindhu, Milan Khealani, Baris Tarimci, Ashima Gupta, Saarthak Malhotra, Pinank Bathvar, Vedant Shah, Simranjeet Bedi, Nyein W. Y Theik, Geetika Kukreja, and Sri U. J Obulareddy
Efficacy of subsequent treatment after combination therapy in non-clear cell renal cell carcinoma (nccRCC), Paulo Siqueira do Amaral, Aniko Szabo, Clara Hwang, Pooja Ghatalia, Abhishek Tripathi, Hannah Dzimitrowicz McManus, Hamid Emamekhoo, Jennifer King, Benjamin L. Maughan, Yousef Zakharia, Pedro C. Barata, Arpita Desai, Melissa A. Reimers, Yasser Ged, Elisabeth I. Heath, Mehmet Asim Bilen, James Brugarolas, Brian I. Rini, Rana R. McKay, and Deepak Kilari
Efficacy of subsequent treatment after combination therapy in non-clear cell renal cell carcinoma (nccRCC), Paulo Siqueira do Amaral, Aniko Szabo, Clara Hwang, Pooja Ghatalia, Abhishek Tripathi, Hannah Dzimitrowicz McManus, Hamid Emamekhoo, Jennifer King, Benjamin L. Maughan, Yousef Zakharia, Pedro C. Barata, Arpita Desai, Melissa A. Reimers, Yasser Ged, Elisabeth I. Heath, Mehmet A. Bilen, James Brugarolas, Brian I. Rini, Rana R. McKay, and Deepak Kilari
Defining complete axillary node burden in cTl/T2 cNO patients undergoing primary surgery with mastectomy and 3 positive sentinel nodes, Hemi Thaker, Theresa Schwartz, Christine Joliat, Drishti Lall, Rachel Fan, Lindsay Petersen, Anna Lehrberg, Laura Dalla Vecchia, and Jessica Bensenhaver
Defining complete axillary node burden in cT1/T2 cN0 patients undergoing primary surgery with mastectomy and 3 positive sentinel nodes, Hemi Thaker, Theresa Schwartz, Christine Joliat, Drishti Lall, Rachel Fan, Lindsay Petersen, Anna Lehrberg, Laura Dalla Vecchia, and Jessica M. Bensenhaver
Reduced Survival in Black Patients With EGFR-Mutant NSCLC, B. Waissengrin, Radhika Gutta, S. Y. Choi, E. Vail, K. Sankar, H. Ramakrishnan, K. Sharma, John Sherwood, Jahnavi Ethakota, A. McKheen, J. Figueiredo, Fawzi Abu Rous, and K. Reckamp
Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study, M. Wiesweg, Shirish M. Gadgeel, B. Cho, S. Lu, E. Felip, H. Hayashi, A. Spira, B. Besse, M. Thomas, S. Owen, Y. Kim, S. Lee, J. Mourao, Y. Lee, Y. Zhao, Y. Fang, N. Girard, Z. Liu, P. Sun, S. Cunha Souza Oliveira, H. Shen, L. Paz-Ares, S. Matsumoto, H. Tanaka, A. Ahmad, T. Andabekov, P. Sunpaweravong, Ö. Özyilkan, J. Yang, M. Gottfried, O. Hernandez, M. Kimmich, D. Cortinovis, and D. Kaen
HMGA2 Predicts Treatment Outcome in Pancreatic Cancer, Naomi Yamamoto, Stephanie Dobersch, Ian Loveless, Annie N. Samraj, Gun Ho Jang, Miki Haraguchi, Liang-I Kang, Marianna B. Ruzinova, Kiran R. Vij, Jacqueline L. Mudd, Thomas Walsh, Rachael A. Safyan, E. Gabriela Chiorean, Sunil R. Hingorani, Nathan M. Bolton, Li Li, Ryan C. Fields, David G. DeNardo, Faiyaz Notta, Howard C. Crawford, Nina G. Steele, and Sita Kugel
Initial Results From Phase 1/2 Study of the RET-Selective Inhibitor Vepafestinib in Patients With RET-Aberrant Solid Tumors, K. Yoh, Y. Shinno, V. Velcheti, V. Subbiah, N. Lakhani, K. Ohashi, Shirish M. Gadgeel, S. Kitano, M. Johnson, H. Wakelee, A. Ono, K. Nishino, E. Miyauchi, T. Kurata, and A. Drilon
Initial Results From Phase 1/2 Study of the RETSelective Inhibitor Vepafestinib in Patients With RETAberrant Solid Tumors, K. Yoh, Y. Shinno, V. Velcheti, V. Subbiah, N. Lakhani, K. Ohashi, Shirish M. Gadgeel, S. Kitano, M. Johnson, H. Wakelee, A. Ono, K. Nishino, E. Miyauchi, T. Kurata, and A. Drilon
Single-Cell RNA Sequencing Reveals Subtype-Specific Resistance Mechanisms to TROP2-Targeted ADCs in Non-Small Cell Lung Cancer, O. Younis, A. Al Bzour, N. Al Bzour, M. Hashki, J. Al Rawabdeh, B. Ricciuti, and Fawzi Abu Rous
Single-Cell RNA Sequencing Identifies ALCAM and Gpnmb as Therapeutic Targets for ADC Development∗bull;∗bull;∗bull; in Squamous Cell Carcinoma of the Lung, O. Younis, J. Al Rawabdeh, A. Al Bzour, N. Al Bzour, M. Hashki, B. Ricciuti, and Fawzi Abu Rous
Single-Cell RNA Sequencing Identifies ALCAM and Gpnmb as Therapeutic Targets for ADC Development in Squamous Cell Carcinoma of the Lung, O. Younis, J. Al Rawabdeh, A. Al Bzour, N. Al Bzour, M. Hashki, B. Ricciuti, and Fawzi Abu Rous
Integrin-D6 Modulates the Tumor Microenvironment q and Serves as a Prognostic Marker in Lung Squamous Cell Carcinoma, O. Younis, J. Al Rawabdeh, N. Al Bzour, M. Hashki, A. Al Bzour, and Fawzi Abu Rous
Integrin-ß6 Modulates the Tumor Microenvironment and Serves as a Prognostic Marker in Lung Squamous Cell Carcinoma, O. Younis, J. Al Rawabdeh, N. Al Bzour, M. Hashki, A. Al Bzour, and Fawzi Abu Rous
MM-423: Secondary Hematologic Malignancies in Patients With Multiple Myeloma: A Retrospective Analysis of Risk Factors and Incidence in a Large Urban Health System, Markie Zimmer, Jamie T. C Abad, Jaya Gupta, Sunita Ghosh, and Philip Kuriakose
Submissions from 2024
Real-world outcomes in patients with biomarker-selected early-stage non-small cell lung cancer, Fawzi Abu Rous, Jesse Sussell, Celina Ngiam, Qing Zhang, Thomas Majda, Daniel Sheinson, Sarika Ogale, Ilze Bara, Katja Schulze, and Shirish M. Gadgeel
PP01.107 Patient Characteristics and Treatment Patterns in Biomarker Selected Early Non-Small Cell Lung Cancer, Fawzi Abu Rous, Jesse Sussell, Celina Ngiam Kochounian, Qing Zhang, Thomas Majda, Danny Sheinson, Sarika Ogale, Ilze Bara, and Shirish Gadgeel
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial, Joachim Aerts, Luis G. Paz-Ares, Carole Helissey, Federico Cappuzzo, Gilles Quere, Dariusz Kowalski, Jose Carlos Benitez Sr., Florian Guisier, Benjamin Besse, Shirish M. Gadgeel, Thomas Wehler, Ignacio Gil-Bazo, Michael Jon Chisamore, Cem Gorgun, Ilhan Celik, Marie Holst Mørch, Patricia Garrido Castro, Teng Jin Ong, and Enriqueta Felip
A comprehensive analysis of the molecular landscape of HER3 expression in adenocarcinoma of the lung, S. K. Alhushki, A. N. Al-Bzour, N. N. Al-Bzour, H. M. Abushukair, and Fawzi Abu Rous
PP01.114 Outcomes of Patients Diagnosed with Lung Cancer after COVID-19 Infection, Zaid Al-Saheli, Omar Ammari, Linda Albusoul, Fawzi Abu Rous, and Shirish Gadgeel
The Polymerase Epsilon Gene Expression and Mutation Predictive Significance in Patients Receiving Immune Checkpoint Inhibitors (icis) for Non-small Cell Lung Cancer (NSCLS), A. Alshurafa, S. Alhushki, D. Alfaqheri, H. Abushukair, B. N. Alzghoul, and Fawzi Abu Rous
Black/African American participation in cancer clinical trials: A qualitative study of community members, patients with cancer, and survivors (Detroit, MI) using CBPR, Sylvester Antwi, Linda Kaljee, Doreen Dankerlui, Eleanor M. Walker, Harriet Larrious-Lartey, Barbara Brush, Barbara Israel, Donna Harris, Sophia Chue, Nayomi Cawthome, Cassandra Mills, Valerie Ofori Aboah, Gwendolyn Daniels, Livingstone Aduse-Poku, Chris M. Coombe, Zachary Rowe, La'Toshia Patman, Wayne Ramocan, Denise White-Perkins, and Evelyn M. Jiagge
Nuclear exporter protein exportin 1 (XPO1) as a novel therapeutic target in pancreatic neuroendocrine tumors, A. S. Azmi, M. H. Uddin, S. F. Bannoura, H. M. Khan, Maria Diab, S. Kim, E. Beal, M. Tobon, H. Chen, R. Beydoun, G. Dyson, R. M. Mohammad, Philip A. Philip, M. N. Al-Hallak, B. F. El-Rayes, and B. Pasche
EP.17B.03 Impact of Social Economic Status on Patient Reported Outcomes (PROs) In Non-Small Cell Lung Cancer (NSCLC), Julia L. Bachler, Anqi Wang, Laila Poisson, Eric Adjei Boakye, Samantha H. Tam, Shirish Gadgeel, Benjamin Movsas, and Bindu Potugari
EP.17B.03 Impact of Social Economic Status on Patient Reported Outcomes (PROs) In Non-Small Cell Lung Cancer (NSCLC), Julia L. Bachler, Anqi Wang, Laila M. Poisson, Eric Adjei Boakye, Samantha H. Tam, Shirish M. Gadgeel, Benjamin Movsas, and Bindu Potugari
1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours, B. Besse, A. E. Drilon, B. C. Cho, D. R. Camidge, J. Neal, C-C. Lin, S. V. Liu, M. Nagasaka, S. C-H Kao, E. Felip, A. J. Van Der Wekken, C. C. Lin, J. R. Bauman, Shirish Gadgeel, M. Samant, J. Shen, Y. Sun, V. W. Zhu, V. A. Upadhyay, and J. J. Lin
XMT-1660: A phase I, first-in-human trial of a B7-H4-directed dolasynthen antibody-drug conjugate in ovarian, endometrial, and breast cancers, Robert Burger, Erika Hamilton, Sylvia Adams, Hyo Han, Alexander Spira, Antonio Giordano, Arvind Chaudhry, Ritesh Parajuli, Judy Wang, Amy Weise, Nour Abuhadra, Patrick McNamara, and Kevin Kalinsky
XMT-1660: A phase I, first-in-human trial of a B7-H4-directed dolasynthen antibody-drug conjugate in ovarian, endometrial, and breast cancers, Robert Burger, Erika Hamilton, Sylvia Adams, Hyo Han, Alexander Spira, Antonio Giordano, Arvind Chaudhry, Ritesh Parajuli, Judy Wang, Amy Weise, Nour Abuhadra, Patrick McNamara, and Kevin Kalinsky
RGI-2001 with CNI-Based Prophylaxis Demonstrates Better Acute Gvhd-Free Survival Following Myeloablative Allohct without Increased Relapse: Comparison of a Multi-Center Phase 2b Study with a Contemporaneous CIBMTR Cohort, Yi-Bin Chen, Shatha Farhan, Lazaros J. Lekakis, Gary J. Schiller, Jean A. Yared, Markus Y. Mapara, Amer Assal, Hannah Choe, Zachariah DeFilipp, Dana D. Lee, Hayley Lane, Linda J. Burns, Mei-Jie Zhang, Matthew Bye, Ted A. Gooley, and Ayman Saad
Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1, A. C. Chiang, M. E. Olmedo Garcia, J. Carlisle, A. Dowlati, N. Reguart, E. Felip, P. J. Jost, N. Steeghs, R. Stec, Shirish Gadgeel, H. H. F Loong, W. Jiang, A. Hamidi, A. Parkes, and L. Paz-Ares
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCC, Byoung Chul Cho, Omid Hamid, Xinhua Zhu, Bhumsuk Keam, John M. Kaczmar, Stephen K. Williamson, Ariel E. Birnbaum, Afshin Dowlati, Grace K. Dy, Steven Jeffrey Hager, Filipa Lynce, Raymond S. McDermott, Debashis Sarker, Amy M. Weise, Timothy A. Yap, Emrullah Yilmaz, Fang Fang, Jayakumar Mani, Glenn Scott Kroog, and Kyriakos P. Papadopoulos
Characterizing outcomes of biliary tract cancers (BTC) with b-catenin (CTNNB1) alterations, Lydia D. Chow, Diana L. Hanna, Rituparna Ganguly, Yasmine Baca, Jonathan Pai, Ani Misirian, Sandra Algaze, Mehmet Akce, Philip A. Philip, Syma Iqbal, Rachna T. Shroff, Heinz-Josef Lenz, Tanios S. Bekaii-Saab, and Anthony B. El-Khoueiry
INSIGHT INTO ATHN 16: TREATMENT OF BLEEDING EVENTS IN PATIENTS WITH CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS TO EVALUATE THE SAFETY OF COAGULATION FACTOR VIIA (RECOMBINANT)-JNCW, Tammuella Chrisentery-Singleton, Suchitra Acharya, Sanjay Ahuja, Lauren Amos, Meera Chitlur, Miguel Escobar, Ashley Eason, Shveta Gupta, Phillip Kuriakose, Sharon Pennington, Rajiv Pruthi, Michael Recht, Spencer Sullivan, Doris Quon, Allison Wheeler, and Mark Reding
INSIGHT INTO ATHN 16: TREATMENT OF BLEEDING EVENTS IN PATIENTS WITH CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS TO EVALUATE THE SAFETY OF COAGULATION FACTOR VIIA (RECOMBINANT)-JNCW, Tammuella Chrisentery-Singleton, Suchitra Acharya, Sanjay Ahuja, Lauren Amos, Meera Chitlur, Miguel Escobar, Ashley Eason, Shveta Gupta, Phillip Kuriakose, Sharon Pennington, Rajiv Pruthi, Michael Recht, Spencer Sullivan, Doris Quon, Allison Wheeler, and Mark Reding
Fractionated docetaxel (D) and radium 223 (Ra223) in metastatic castration-resistant prostate cancer (CRPC): A modular phase I trial, Brendan Connell, Clara Hwang, Edmund Folefac, Christian Lawlor, Benjamin Koethe, and Paul Mathew
Fractionated docetaxel (D) and radium 223 (Ra223) in metastatic castrationresistant prostate cancer (CRPC): A modular phase I trial, Brendan Connell, Clara Hwang, Edmund Folefac, Christian Lawlor, Benjamin Koethe, and Paul Mathew
HEALTHCARE-ASSOCIATED INFECTIONS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A NATIONWIDE ANALYSIS, John Cuenca, Bernard Moscoso, Diana Cardenas, Marissa Schettino, Daniel Gonzalez-Mosquera, Pool Tobar, Luis Gonzalez-Mosquera, and Joseph Nates
HEALTHCARE-ASSOCIATED INFECTIONS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A NATIONWIDE ANALYSIS, John Cuenca, Bernard Moscoso, Diana Cardenas, Marissa Schettino, Daniel Gonzalez-Mosquera, Pool Tobar, Luis Gonzalez-Mosquera, and Joseph Nates
Pulsed low dose rate radiation to mitigate tumor-permissive responses in pancreatic cancer-associated fibroblasts: Introducing the HOST-factor, Edna Cukierman, Janusz Franco-Barraza, Tiffany Luong, Kristopher Raghavan, Jessica K. Wong, Débora Barbosa Vendramini Costa, Ralph Francescone, Jaye C. Gardiner, Sanjay S. Reddy, Elizabeth A. Handorf, and Joshua E. Meyer
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATENORTH AMERICA): NRG- GI008, Arvind Dasari, Guan Yu, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Ibrahim H. H Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Christopher H. Lieu
